White Paper
CRITICAL SUCCESS FACTORS FOR LAUNCHING PRODUCTS WITH FAST TRACK, PRIME, OR ILAP DESIGNATION
This EVERSANA white paper examines the commercialization challenges of launching therapies granted FDA Fast Track, EMA PRIME, or UK ILAP designation, which accelerate regulatory review for treatments addressing serious diseases and unmet medical needs. While these pathways shorten time to market, they also compress launch preparation and create uncertainty due to limited clinical data. The paper outlines critical success factors, including early launch planning, patient journey analysis, market segmentation, value and evidence generation, payer engagement, health economic modeling, scenario planning, and cross-functional coordination. It concludes that integrated commercialization strategies, flexible execution, and strong stakeholder education are essential to maximize market access, acce
